World Investment Advisors Makes New Investment in Halozyme Therapeutics, Inc. $HALO

World Investment Advisors purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,014 shares of the biopharmaceutical company’s stock, valued at approximately $674,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Moran Wealth Management LLC lifted its position in shares of Halozyme Therapeutics by 0.4% in the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 151 shares in the last quarter. Coldstream Capital Management Inc. boosted its stake in shares of Halozyme Therapeutics by 1.9% during the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after buying an additional 165 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of Halozyme Therapeutics by 3.0% in the 3rd quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 170 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares during the last quarter. Finally, Private Advisor Group LLC increased its position in shares of Halozyme Therapeutics by 0.8% in the third quarter. Private Advisor Group LLC now owns 23,623 shares of the biopharmaceutical company’s stock valued at $1,733,000 after acquiring an additional 184 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Up 0.5%

Shares of Halozyme Therapeutics stock opened at $67.44 on Tuesday. The firm’s 50-day moving average price is $65.65 and its two-hundred day moving average price is $68.67. The company has a market capitalization of $8.00 billion, a price-to-earnings ratio of 24.26, a PEG ratio of 0.27 and a beta of 0.89. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 12-month low of $51.06 and a 12-month high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.Halozyme Therapeutics’s revenue was up 42.2% compared to the same quarter last year. During the same period last year, the firm posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $63.48, for a total value of $103,155.00. Following the transaction, the director directly owned 38,498 shares in the company, valued at $2,443,853.04. This trade represents a 4.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer directly owned 7,055 shares of the company’s stock, valued at $477,200.20. This represents a 55.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 120,482 shares of company stock valued at $8,200,842. 2.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of analyst reports. Benchmark raised their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Finally, Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $80.67.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.